PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage

  • Authors:
    • Yun‑Fang Zhang
    • Qi Wang
    • Yan‑Yan Su
    • Jie‑Lin Wang
    • Bao‑Jun Hua
    • Shen Yang
    • Jun‑Xia Feng
    • Hong‑Yan Li
  • View Affiliations

  • Published online on: February 13, 2017     https://doi.org/10.3892/mmr.2017.6196
  • Pages: 1786-1792
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long-term peritoneal dialysis (PD) leads to ultrafiltration failure (UFF). Peritoneal mesothelial cells, which form the innermost monolayer of the peritoneal cavity, have been shown to regulate various responses, including inflammation, in UFF. The present study was designed to investigate the effect of the peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) agonist, rosiglitazone, on peritoneal dialysis solution (PDS)‑induced injuries in rat peritoneal mesothelial cells (RPMCs). RPMCs were cultured for different durations and with different concentrations of PDS. The gene expression levels of aquaporin‑1 (AQP‑1) and zonula occluden‑1 (ZO‑1) were determined using reverse transcription‑quantitative polymerase chain reaction analysis. The protein levels of AQP‑1, ZO‑1 and PPAR‑γ were measured using western blot analysis. Interleukin (IL)‑6 and IL‑8 were detected using ELISA. The RPMCs were damaged by stimulation with 4.25% PDS for 72 h. The expression levels of AQP‑1 and ZO‑1 were increased, and the secretion of IL‑6 and IL‑8 were decreased by rosiglitazone. The use of the PPAR‑γ inhibitor, GW‑9662, completely prevented the effects of rosiglitazone. These results indicated that PDS exposure stimulated an inflammatory response in the RPMCs. The PPAR‑γ activator, rosiglitazone, appeared to relieve the injury by inhibiting inflammation, and regulating the expression of AQP‑1 and ZO‑1, however further investigations are required to elucidate the potential underlying mechanism.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 15 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang YF, Wang Q, Su YY, Wang JL, Hua BJ, Yang S, Feng JX and Li HY: PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage. Mol Med Rep 15: 1786-1792, 2017
APA
Zhang, Y., Wang, Q., Su, Y., Wang, J., Hua, B., Yang, S. ... Li, H. (2017). PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage. Molecular Medicine Reports, 15, 1786-1792. https://doi.org/10.3892/mmr.2017.6196
MLA
Zhang, Y., Wang, Q., Su, Y., Wang, J., Hua, B., Yang, S., Feng, J., Li, H."PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage". Molecular Medicine Reports 15.4 (2017): 1786-1792.
Chicago
Zhang, Y., Wang, Q., Su, Y., Wang, J., Hua, B., Yang, S., Feng, J., Li, H."PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage". Molecular Medicine Reports 15, no. 4 (2017): 1786-1792. https://doi.org/10.3892/mmr.2017.6196